Advanced Solutions Life Sciences
Develops robotic 3D bioprinting systems and software for tissue engineering and regenerative medicine, enabling automated fabrication of vascularized tissues and organoids.
- CEO / Founder
- Michael Golway
- Team Size
- 11-50
- Stage
- Active
- Total Funding
- $611.9K
- Latest Round
- Undisclosed
Technology & Products
Key Products
BioAssemblyBot® 3D Biofabrication Technology Platforms, TSIM® and BioApp® Software
Technological Advantage
Patented BioAssemblyBot technology enables precise, automated tissue fabrication with vascularization capabilities, integrated with proprietary TSIM software for end-to-end workflow
Differentiation
Value Proposition
Reduces tissue model development time from months to days through automated 3D bioprinting, enabling high-throughput drug screening and accelerating regenerative medicine research.
How They Differentiate
6-axis robotic arm provides greater freedom of movement and precision compared to typical 3-axis bioprinters, integrated software platform enables automated workflow from design to fabrication
Market & Competition
Target Customers
Pharmaceutical companies, biomedical research institutions, regenerative medicine developers
Industry Verticals
Biotechnology; Pharmaceutical; Medical Research
Competitors
Allevi, CELLINK, Organovo
Growth & Milestones
Growth Metrics
23% employee growth reported; $5M-$7.9M annual revenue
Major Milestones
2013: Company founded; 2018: BioAssemblyBot patent awarded; 2019: Partnership with GE Healthcare Life Sciences; 2025: NH Tech Alliance Product of the Year award
Notable Customers
GE Healthcare Life Sciences (now Cytiva) - strategic R&D and distribution partnership; Advanced Regenerative Medical Institute (ARMI); Drug discoverers, tissue engineers, device developers, and researchers (general customer base)